Cytosorbents Corporation
CTSO
$0.61
$0.023.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.36% | -14.52% | 145.34% | 75.72% | -15.10% |
| Total Depreciation and Amortization | -9.41% | -6.53% | -1.45% | -8.69% | -46.15% |
| Total Amortization of Deferred Charges | 30.37% | 0.00% | 1,881.31% | 1,679.44% | -- |
| Total Other Non-Cash Items | -79.45% | 145.49% | -392.05% | -188.50% | 694.44% |
| Change in Net Operating Assets | 6.35% | -156.29% | 145.46% | 76.82% | -443.27% |
| Cash from Operations | -106.11% | -4.63% | 68.50% | 28.26% | 63.46% |
| Capital Expenditure | -56.52% | 88.82% | -107.30% | 95.35% | 27.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -370.91% | 148.98% | 6.23% | 44.87% | -36.14% |
| Cash from Investing | -134.68% | 118.39% | -10.76% | 62.83% | 8.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -- | 12,742.29% | -98.63% |
| Repurchase of Common Stock | -- | -- | -450.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,383.83% | 100.00% | -100.01% | 1,294.84% | -98.63% |
| Foreign Exchange rate Adjustments | 1,374.53% | -271.76% | 471.20% | 346.55% | -7.51% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.46% | 3.89% | -128.52% | 160.58% | -143.17% |